Denali Therapeutics Inc. (FRA:4DN)
Germany flag Germany · Delayed Price · Currency is EUR
17.75
+1.74 (10.87%)
At close: Jan 23, 2026

Denali Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
--330.53108.4648.66335.66
Revenue Growth (YoY)
--204.74%122.89%-85.50%1158.19%
Cost of Revenue
420.66396.44423.88358.73265.35212.62
Gross Profit
-420.66-396.44-93.35-250.27-216.69123.04
Selling, General & Admin
127.16105.44103.3590.4879.0660.33
Operating Expenses
127.16105.44103.3590.4879.0660.33
Operating Income
-547.82-501.88-196.7-340.74-295.7562.72
Interest Expense
-0.7-0.3----
Interest & Investment Income
35.0729.827.5513.1413.345.7
Other Non Operating Income (Expenses)
-----3.6
EBT Excluding Unusual Items
-513.45-472.36-189.15-327.61-282.4172.01
Gain (Loss) on Sale of Investments
14.7835.1243.951.64-8.75-0.06
Gain (Loss) on Sale of Assets
-14.54----
Pretax Income
-498.68-422.71-145.19-325.97-291.1671.96
Income Tax Expense
0.070.070.030.02-0.580.82
Net Income
-498.74-422.77-145.22-325.99-290.5871.14
Net Income to Common
-498.74-422.77-145.22-325.99-290.5871.14
Shares Outstanding (Basic)
171164137126122109
Shares Outstanding (Diluted)
171164137126122113
Shares Change (YoY)
9.46%19.73%9.43%3.30%7.83%17.88%
EPS (Basic)
-2.91-2.57-1.06-2.60-2.390.65
EPS (Diluted)
-2.91-2.57-1.06-2.60-2.390.63
Free Cash Flow
-410.85-363.61-370.93-262.55-219.89413.06
Free Cash Flow Per Share
-2.40-2.21-2.70-2.09-1.813.67
Gross Margin
---28.24%-230.74%-36.66%
Operating Margin
---59.51%-314.16%-607.78%18.68%
Profit Margin
---43.94%-300.56%-597.15%21.19%
Free Cash Flow Margin
---112.22%-242.06%-451.88%123.06%
EBITDA
-542.07-500.79-179.97-330.36-287.1671.25
EBITDA Margin
---54.45%--21.23%
D&A For EBITDA
5.751.0916.7310.388.598.53
EBIT
-547.82-501.88-196.7-340.74-295.7562.72
EBIT Margin
---59.51%--18.68%
Effective Tax Rate
-----1.14%
Revenue as Reported
--330.53108.4648.66335.66
Source: S&P Global Market Intelligence. Standard template. Financial Sources.